About Eleusis
Eleusis is a company based in London (United Kingdom) founded in 2013 by Charles D. Nichols was acquired by Beckley Psytech in October 2022. Eleusis has raised $1.47 million across 3 funding rounds from investors including Beckley Psytech. The company has 1 employees as of January 31, 2020. Eleusis has completed 1 acquisition, including Kalypso. Eleusis operates in a competitive market with competitors including ATAI, Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics and Alpine Immune Sciences, among others.
- Headquarter London, United Kingdom
- Employees 1 as on 31 Jan, 2020
- Founders Charles D. Nichols
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eleusis Holdings Limited
- Date of Incorporation 08 Jun, 2017
- Jurisdiction PIMLICO, LONDON, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.47 M (USD)
in 3 rounds
-
Latest Funding Round
$465 K (USD), Seed
Mar 04, 2022
- Investors
-
Employee Count
1
as on Jan 31, 2020
- Investments & Acquisitions
-
Acquired by
Beckley Psytech
(Oct 24, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Eleusis
Eleusis has successfully raised a total of $1.47M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $465 thousand completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eleusis
Eleusis has secured backing from 1 investor. Prominent investors backing the company include Beckley Psytech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of drugs for the treatment of neurological and psychiatric disorders
|
Locked | Locked | Locked |
Investor details for Eleusis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eleusis
Eleusis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Kalypso.
Investment portfolio details for Eleusis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Chain of wellness centers
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Eleusis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Eleusis
Detailed financials for Eleusis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eleusis Comparisons
Peer comparison for Eleusis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eleusis
Eleusis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics and Alpine Immune Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
Therapies for mental disorders, including psilocybin for depression, are developed.
|
Detailed competitors of Eleusis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eleusis
Complete news archive for Eleusis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eleusis
Eleusis was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Eleusis is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Eleusis is a funded company, having raised a total of $1.47M across 3 funding rounds to date.
As of Jan 31, 2020, the latest employee count at Eleusis is 1.
Eleusis was founded in 2013 in London, United Kingdom, as a developer of medicines targeting immunomodulation and neuroprotection. A portfolio of drug candidates has been established to address unmet medical needs in psychiatry and other areas. The lead program, ELE-Psilo, is focused on depression treatment. Operations center on advancing these candidates through clinical development in the biotechnology sector.
Eleusis's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Eleusis has made 1 acquisition, including Kalypso.
Eleusis has 1 investor. Key investors include Beckley Psytech.